Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Heather E. Wheeler et al.|Clinical Cancer Research|2016Cited by 57
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|Cancer|2014Cited by 35
Pandemic Influenza Preparedness: A Patient Care and Team Training SimulationJohn F. Mahoney, Barbara Offen, Joe Suyama|MedEdPORTAL|2009Cited by 4
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyMichael J. Kelley, Daniel L. Hertz, Yusuke Nakamura et al.|Loyola eCommons (Loyola University of Chicago)|2020Cited by 4
A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).Daniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Journal of Clinical Oncology|2013Cited by 1